Navigation Links
A*STAR scientists discover potential drug for deadly brain cancer
Date:9/4/2012

1. A*STAR scientists have identified a biomarker of the most lethal form of brain tumours in adults- glioblastoma multiforme. The scientists found that by targeting this biomarker and depleting it with a potential drug, they were able to prevent the progression and relapse of the brain tumour.

2. This research was conducted by scientists at A*STAR's Institute of Medical Biology led by Dr Prabha Sampath, Principal Investigator, in collaboration with A*STAR's Bioinformatics Institute (BII), and clinical collaborators from Medical University of Graz, Austria, and National University of Singapore. The research findings were published on Aug 23 in the scientific journal, Cell Reports from Cell Press.

3. The scientists found that the biomarker, miR-138, is highly expressed in cancer stem cells compared to normal neural stem cells. They thus carried out in vitro experiments to deplete miR-138 in these cancer stem cells with a potential drug, antimiR-138, to observe the effect. They found that when miR-138 is depleted, the cancer cells are completely destroyed. This is an important breakthrough as current therapies such as gamma radiation and surgical methods proved to be inadequate in treating these brain tumours, which tend to re-grow from cancer stem cells and become extremely lethal.

4. Dr Sampath said, "In this study we have identified a master regulator, miR-138, which is essential for the progression and relapse of a deadly form of brain cancer. By targeting this regulator we can effectively prevent the recurrence of this lethal form of cancer. This promising finding will pave the way for the development of a novel therapy to successfully treat the aggressive forms of brain cancer."

5. Studies were also done in mice to determine whether antimiR-138 could effectively inhibit the growth of tumours. These experiments were conducted with a control drug as well, revealing that tumours continued to be present when mice were injected with the control, while injection with the antimiR-138 showed no tumour growth after nine months.

6. Dr Alan Colman, Executive Director of Singapore Stem Cell Consortium and a Principal Investigator at IMB said, "Malignant gliomas are a particularly devastating and lethal form of human brain cancer. As with a growing number of other cancers, evidence is accumulating that the persistence and chemo-resistance of this cancer is due to the presence of glioma stem cells (GSCs). In this exciting publication, Sampath and colleagues indicate that in the tumours, these GSCs express the microRNA-138 (miR-138) and that the targeted elimination of this RNA markedly reduced the growth and survival of GSCs in cell culture. This work highlights the possible significance of miR-138 as a prognostic biomarker and also suggests miR-138 synthesis as a target for therapeutic intervention."

7. Prof Sir David Lane, Chief Scientist at A*STAR, added, "These findings will facilitate the translation of basic research into clinical applications such as targeted drug design to treat brain cancer. This is an excellent example of how A*STAR's impactful research can be applied to develop treatments for diseases like cancer."

8. Dr Sampath was a recipient of the A*STAR Investigatorship Award in 2007, a prestigious research award designed to attract the most promising young researchers from around the world to do independent research at A*STAR.


'/>"/>

Contact: Vithya Selvam
vithya_selvam@a-star.edu.sg
656-826-6291
Agency for Science, Technology and Research (A*STAR), Singapore
Source:Eurekalert  

Related biology news :

1. Breakthroughs in Chikungunya research from A*STAR spell new hope for better treatment and protection
2. Singapore scientists find genes associated with glaucoma, a major cause of eye blindness
3. EARTH: Antarctic trees surprise scientists
4. Rice, MD Anderson scientists probe mystery of operon evolution
5. Coral scientists use new model to find where corals are most likely to survive climate change
6. Scientists call policy-makers to be scale-aware
7. Chinese scientists successfully crack the genome of diploid cotton
8. Scientists find oldest occurrence of arthropods preserved in amber
9. To cap or not to cap: Scientists find new RNA phenomenon that challenges dogma
10. MBL scientists discover nerves control iridescence in squid’s remarkable electric skin
11. Scientists identify new gene that influences survival in ALS
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
A*STAR scientists discover potential drug for deadly brain cancer
(Date:9/7/2018)... ... September 05, 2018 , ... Following up on ... late last year, IPS-Integrated Project Services, LLC and G-CON Manufacturing have successfully designed ... The iCON solution provides a pre-fabricated modular cleanroom infrastructure for the drug manufacturers’ ...
(Date:9/1/2018)... ... August 31, 2018 , ... Right this minute, Frenchman Ben Lecomte is hard at work ... in 1998, he’s taken on a new challenge: going from Tokyo to San Francisco, churning ... his team on the support boat. As the first expedition of its kind, The Swim ...
(Date:8/31/2018)... MADISON, Wisc. (PRWEB) , ... August 30, 2018 ... ... to measure inhibitor residence times as a component of drug discovery programs. Longer-target ... deriving these residence times are low throughput, require expensive instrumentation, or require the ...
Breaking Biology News(10 mins):
(Date:9/15/2018)... ... 2018 , ... Nationally recognized public accounting and consulting firm Cherry Bekaert ... the Firm’s Nashville practice, on her appointment to Launch Tennessee’s Board of ... Managing Partner of the Firm’s Nashville practice in December 2017 . In this role, ...
(Date:9/12/2018)... ... 12, 2018 , ... NDA Partners Chairman Carl Peck, MD, ... of Regulatory Affairs and Quality Systems at WellDoc, Inc., has joined the firm ... Quality Systems at WellDoc, Inc., she conducted quality control and supplier audits, led ...
(Date:9/7/2018)... ... ... Akadeum Life Sciences today announced it has appointed George Dunbar to its ... numerous biotech companies. , He most recently served as president and CEO of ... in St. Louis, MO. Prior to ISTO, he was a Venture Partner with ...
(Date:8/29/2018)... ... 28, 2018 , ... Cognition Corporation ®, a software company specializing in ... NAVIGATE2018 . , Ryan Ward, Director of Engineering at Zimmer Biomet, has been ... engineer and manager with Zimmer Biomet for almost 15 years, Mr. Ward will focus ...
Breaking Biology Technology: